

DRI HEALTHCARE TRUST DISCLOSURE POLICY

Objective and Scope

The objective of this disclosure policy (the “**Policy**”) is to ensure that communications to the public about DRI Healthcare Trust (the “**Trust**”) and any of its subsidiaries (collectively, “**DRI Healthcare**”) are timely, factual and accurate, and broadly disseminated in accordance with all applicable legal and regulatory requirements.

Disclosure Committee

The board of trustees of the Trust (the “**Board of Trustees**”) has established a disclosure committee (“**Disclosure Committee**”) responsible for overseeing DRI Healthcare’s disclosure practices. The Disclosure Committee consists of the Executive Chair, the Chief Executive Officer, the Chief Financial Officer and a designated representative from the Legal Department, or their respective function equivalents.

A representative from the Legal Department of DRI Healthcare will attend all Disclosure Committee meetings and will serve as Secretary.

General Responsibilities

The Disclosure Committee is responsible for:

1. overseeing the implementation of this Policy and the education of employees, officers and trustees about this Policy and disclosure issues;
2. making determinations on whether facts or information is material or required to be publicly disclosed;
3. designing, establishing or causing to be established, and maintaining controls and other procedures (which may include procedures currently used by the Trust as described under the heading “Disclosure Controls and Procedures”) that are intended to provide reasonable assurance that:
 - (a) material information required to be disclosed by the Trust to securities regulatory authorities and other written information that the Trust discloses to the investment community and the public is recorded, processed, summarized and reported accurately and without omission of any material fact necessary to make the information not misleading and is made on a timely basis;
 - (b) financial information disclosed by the Trust fairly presents in all material respects the financial condition, results of operations and cash flows of DRI Healthcare as of and for the periods presented therein; and,
 - (c) information is accumulated and communicated to management, including the CEO, CFO and the Disclosure Committee, as appropriate to allow timely decisions regarding such required disclosure;
4. monitoring the integrity and effectiveness of DRI Healthcare’s Disclosure Controls and Procedures on an ongoing basis;

5. reviewing and supervising the preparation of statements made by or on behalf of DRI Healthcare (collectively, the “**Disclosure Statements**”) in:
 - (a) all written documents required to be filed by the Trust with securities regulators pursuant to securities legislation, regulations and rules;
 - (b) press releases and other communications to unitholders and the public;
 - (c) presentations to analysts, the investment community, rating agencies and lenders; and
 - (d) information to be included on the Trust’s website or otherwise electronically communicated to the public;
6. monitoring the integrity and effectiveness of DRI Healthcare’s Disclosure Controls and Procedures on an ongoing basis, including evaluating their effectiveness in connection with each fiscal year end; and
7. periodically reviewing and recommending any material changes to this Policy for review by the Audit Committee of the Trust and approval by the Board of Trustees.

The Disclosure Committee will report to the Board of Trustees on an annual basis with respect to compliance with this Policy and its effectiveness and, if appropriate, recommend changes to this Policy to comply with changing regulatory requirements.

Disclosure Controls and Procedures

The Disclosure Committee will establish specific procedures and timetables that shall be adhered to by DRI Healthcare and the trustees, executive officers and employees of DRI Healthcare for the preparation and, wherever practicable, review by such personnel, as well as by the auditors and external legal counsel, as the Disclosure Committee may determine, and, ultimately, the dissemination of, all Disclosure Statements in compliance with this Policy. The Disclosure Committee may elect to, at any time, adopt controls and procedures that are different than those which have been previously established, provided that such controls and procedures, in the opinion of the Disclosure Committee, provide satisfactory assurance that Disclosure Statements are disclosed in compliance with this Policy and all applicable securities laws.

The Disclosure Controls and Procedures will involve the following:

1. identifying all continuous disclosure requirements under securities laws, rules and policies applicable to DRI Healthcare;
2. identifying the individuals responsible for preparing reportable information and individuals, whether internal or external, responsible for reviewing reports or portions of reports to verify disclosure made with respect to their areas of responsibility or expertise;
3. establishing timetables for the preparation and adequate review of reportable information;
4. procedures for obtaining “sign-off” on disclosure of reportable information;
5. procedures for the identification and timely reporting to senior management and the Disclosure Committee of information which may constitute Material Information or a change in Material Information that had previously been publicly disclosed;

6. documenting the procedures followed with respect to the release of each disclosure made in writing and for the review of any disclosure made orally; and
7. ongoing evaluation of DRI Healthcare's Disclosure Controls and Procedures.

Principles of Disclosure of Material Information

“**Material Information**” has the meaning given in DRI Healthcare's Insider Trading and Blackout Policy. Examples of developments that may give rise to Material Information include, but are not limited to, those set out in Appendix A.

In connection with disclosure obligations under applicable laws and stock exchange rules, DRI Healthcare will adhere to the following basic disclosure principles:

1. Unless otherwise determined by the Disclosure Committee, Material Information will be publicly disclosed immediately via news release.
2. In certain circumstances, the Disclosure Committee may determine that immediate disclosure would be unduly detrimental to DRI Healthcare (for example if release of the information would prejudice negotiations in a corporate transaction), in which case the information will be kept confidential until the Disclosure Committee determines it is appropriate to publicly disclose. In such circumstances, the Disclosure Committee will determine how that information will be controlled and will consider whether a confidential material change report is required to be filed with applicable securities regulators.
3. Disclosure must include any information, the omission of which would make the rest of the disclosure misleading (half-truths are misleading).
4. Unfavourable Material Information must be disclosed as promptly and completely as favourable information. The Disclosure Committee shall endeavour to ensure that its approach to materiality is consistent.
5. Disclosure of forward-looking information will be made in accordance with the procedures set out in this Policy under “Forward Looking Information”.
6. There will be no selective disclosure. Material information which has not been publicly disclosed must not be disclosed to selected individuals (for example, in an interview with an analyst or in a telephone conversation with an investor). If previously undisclosed Material Information has been inadvertently selectively disclosed, such information must be broadly disclosed immediately via news release. Pending such public disclosure, DRI Healthcare shall contact the stock exchanges on which its securities trade and, if necessary, request that trading in its securities be halted.
7. Disclosure on DRI Healthcare's website alone does not constitute adequate disclosure of Material Information.
8. Disclosure must be corrected immediately if DRI Healthcare subsequently learns that earlier disclosure by DRI Healthcare contained a material error at the time it was given. In addition, prompt disclosure is required of any significant changes to previously disclosed information where that information becomes misleading as a result of subsequent events.

9. DRI Healthcare must file a material change report with appropriate regulatory authorities concerning any material change as soon as practicable and in any event within 10 days of the date on which the change occurs.

In the event of any question as to whether or not facts or information constitute Material Information requiring disclosure, the Disclosure Committee will make the final determination, unless the Board of Trustees otherwise determines that disclosure should be made.

Trading Restrictions and Blackout Periods

It is illegal for anyone to purchase or sell securities of any public company with knowledge of Material Information affecting that company that has not been publicly disclosed. Except in the necessary course of business, it is also illegal for anyone to inform any other person of non-public Material Information. Therefore, trustees, executive officers and employees of DRI Healthcare (including those with knowledge of confidential or Material Information about DRI Healthcare or counterparties in negotiations of material potential transactions) are prohibited from trading Trust securities or securities of any such counterparty until the information has been fully disclosed and a reasonable period of time has passed for the information to be widely disseminated. These restrictions are described in more detail in the Trust's Insider Trading and Blackout Policy.

Reporting insiders

Under securities laws, certain persons connected to DRI Healthcare are also required to file insider reports disclosing their interest in securities and related financial instruments of the Trust. Such persons include the "Reporting Insiders" as determined in accordance with DRI Healthcare's Insider Trading Policy.

Initial insider reports are required to be filed within 10 calendar days of the reporting insider becoming a reporting insider of DRI Healthcare. Filing a subsequent insider report in respect of any change in such ownership or interest in the Trust's securities is required within five calendar days.

Maintaining Confidentiality

Any employee privy to confidential information is prohibited from communicating such information to anyone else, unless it is necessary to do so in the necessary course of business. Efforts will be made to limit access to such confidential information to only those who need to know the information and such persons will be advised that the information is to be kept confidential.

Outside parties privy to undisclosed Material Information concerning DRI Healthcare will be bound by obligations of confidentiality and must not divulge such information to anyone else, other than in the necessary course of business and that they may not trade in the Trust's securities until the information is publicly disclosed.

Disclosure in the necessary course of business will generally cover communications with:

- DRI Healthcare's trustees, executive officers and employees;
- lenders, legal counsel, auditors, underwriters, accountants, investment bankers and consultants;
- credit rating agencies under contract with DRI Healthcare;
- customers, suppliers, or strategic partners where the communications are relevant to DRI Healthcare's business with them;

- government and government agencies and non-government regulators.

However, the necessary course of business exception does not cover communications to the media, analysts, institutional investors or other market professionals even if they expressly agree to maintain the disclosed information in confidence.

In order to prevent the misuse or inadvertent disclosure of non-public Material Information, the procedures set forth below should be observed at all times:

1. Documents and files containing confidential information should be kept in a safe place to which access is restricted to individuals who “need to know” that information in the necessary course of business and code names should be used, if necessary.
2. Confidential matters should not be discussed in places where the discussion may be overheard, such as elevators, hallways, restaurants, airplanes or taxis.
3. Confidential documents should not be read or displayed in public places and should not be discarded where others can retrieve them.
4. Employees must ensure they maintain the confidentiality of information in their possession outside of the office as well as inside the office.
5. Transmitting documents by electronic means, such as by email or directly from one computer to another, should be made only where it is reasonable to believe that the transmission can be made and received under secure conditions.
6. Unnecessary copying of confidential documents should be avoided and documents containing confidential information should be promptly removed from conference rooms and work areas after meetings have concluded. Extra copies of confidential documents should be shredded or otherwise destroyed.
7. Access to confidential electronic data should be restricted through the use of passwords or other applicable encryption technology.
8. Security over electronic devices through which confidential information is accessed, stored or transmitted should be maintained at all times.

Designated Spokespersons

DRI Healthcare designates a limited number of spokespersons responsible for communication with the investment community, regulators or the media. The Executive Chair and CEO of the Trust shall be the official spokespersons for DRI Healthcare (“**Spokespersons**”). Others within DRI Healthcare or DRI Healthcare’s consultants, advisors or public relations service providers may be designated by the Disclosure Committee to respond to, or assist in responding to, specific inquiries as necessary or appropriate.

Employees who are not authorized spokespersons must not respond, under any circumstances, to inquiries from the investment community, the media or others, unless specifically asked to do so by an authorized Spokesperson. All routine inquiries from analysts and investors shall be referred to the Executive Chair or CEO of the Trust. The Executive Chair or CEO of the Trust are authorized to provide such information as is publicly available and answer such questions based on previously available public information. Inquiries beyond previously available information shall be referred to the Disclosure Committee to assess whether further disclosure or supplementary information to previous disclosure needs to be released.

News Releases

News releases respecting Material Information should contain sufficient detail to enable the media and investors to understand the substance and importance of such information while avoiding exaggerated reports or promotional commentary.

If the stock exchange(s) upon which units of the Trust are listed is open for trading at the time of a proposed announcement of Material Information, prior notice of the proposed news release must be pre-filed with, and acceptance received from, the Market Surveillance Department of the Canadian Investment Regulatory Organization (“**Market Surveillance**”), through such means permitted by the market surveillance department(s). Market Surveillance must also be advised of the proposed method of dissemination of the press release.

If a proposed announcement does not contain material information or the exchange upon which securities of the Trust are listed is not open for trading at the time of a proposed announcement of material information, Market Surveillance staff should be advised before trading opens on the next trading day and a copy of the press release must be provided to Market Surveillance through such permitted means as designated by Market Surveillance.

Annual and interim financial results will be publicly released as soon as practicable following the approval of the financial statements by the trustees of the Trust. The disclosure of financial performance measures, ratios or supplemental financial measures that do not have a standardized meaning under International Financial Reporting Standards (“IFRS”) used in the DRI Healthcare's financial disclosures (“non-IFRS financial measures”) risks misleading investors if such measures are not accompanied by appropriate disclosure. In order to ensure that a non-IFRS financial measure does not mislead investors, DRI Healthcare's disclosure shall comply with the requirements in National Instrument 52-112 – *Non-GAAP and Other Financial Measures Disclosure*.

News releases will be disseminated through an approved news wire service that provides simultaneous national and/or international distribution. News releases will be transmitted to all stock exchange members, relevant regulatory bodies, major business wires, national financial media and the local media in areas where DRI Healthcare has its headquarters and operations.

News releases will be posted on DRI Healthcare’s website immediately after release over the news wire. The news release page of the website shall include a notice that advises the reader that the information posted was accurate at the time of posting, but may be superseded by subsequent public disclosure.

Conference Calls

If deemed necessary, and appropriate, conference calls may be held for quarterly earnings and major developments, whereby discussion of key aspects is accessible simultaneously to all interested parties, some as participants by telephone and others in a listen-only mode by telephone or via a webcast over the Internet. The call will be preceded by a news release containing all relevant Material Information.

At the beginning of the conference call, a Spokesperson or the call operator, upon instruction by the Spokesperson, shall notify all participants to the call that there may be discussion of forward-looking information on the call. The Spokesperson or operator shall then provide appropriate cautionary language with respect to any such forward-looking information and direct participants to publicly filed disclosure documents containing the assumptions, sensitivities and a full discussion of the risks and uncertainties that could affect such forward-looking statements.

DRI Healthcare will provide advance notice of the conference call and/or webcast by issuing a news release



announcing the date and time and providing information on how interested parties may access the call and/or webcast. In addition, DRI Healthcare may send invitations to analysts, institutional investors, the media and others to participate. A recording of the conference call and/or an archived audio webcast on the internet will be made available following the call for a minimum of seven days, for anyone interested in listening to a replay.

Rumours

DRI Healthcare will not comment, affirmatively or negatively, on rumours. This also applies to rumours on the internet. If an employee is aware of a material rumour, they shall advise the Disclosure Committee for consideration. However, should any stock exchange on which securities of the Trust is trading that the Trust make a definitive statement in response to a market rumour that is causing significant volatility in the Trust's units, the Disclosure Committee will consider the matter and take appropriate action.

Contacts with Analysts and Investors

Disclosure in individual or group meetings does not constitute adequate disclosure of information that is considered non-public Material Information. If DRI Healthcare intends to announce Material Information at an analyst or unitholders' meeting or a press conference or conference call, the announcement must be preceded by a news release.

DRI Healthcare recognizes that meetings with analysts and significant investors are an important element of DRI Healthcare's investor relations program. DRI Healthcare will meet with analysts and investors on an individual or small group basis as needed and will initiate contacts or respond to analyst and investor calls in a timely, consistent and accurate fashion in accordance with this Policy.

DRI Healthcare will provide only non-Material Information through individual and group meetings, in addition to regular publicly disclosed information. DRI Healthcare cannot alter the materiality of information by breaking down the information into smaller, non-material components.

DRI Healthcare may maintain a "frequently asked questions" section on its website and may post information similar to the non-Material Information provided in individual investor and group meetings.

Contacts with Media

It is our policy that only the Spokespersons speak to any media (including print, broadcast and electronic media) concerning DRI Healthcare or any of its business activities. On occasion, it may be appropriate for other individuals to speak with the media; however, prior approval must be obtained from the Disclosure Committee.

Unless otherwise indicated herein, media communications must receive approval of at least two members of the Disclosure Committee prior to their issuance. The approval must include a review of the final text of the communications

The media may contact our offices or sites for various types of information relating to DRI Healthcare and its business. Employees approached by the media should direct all calls to the Spokespersons.

If the media contacts an employee by any means (including phone, personal visit, or e-mail) with a request for information, they should do the following:

- inquire as to the information that is being requested;
- inquire as to the purpose of the information request;



- inquire when the story is expected to be published or run on the radio or television;
- inquire what their deadline is for a response from DRI Healthcare;
- ask for all contact information; and
- notify the Disclosure Committee immediately.

In some cases, it may be decided by the Disclosure Committee that an individual other than a Spokesperson should respond to a specific media request. In such an instance, the following guidelines shall be adhered to by the designated individual:

- provide a draft of the media release, or contents of the message to be delivered to the Disclosure Committee for approval;
- in the case of a media request, the media release shall confirm facts only, and only information which has previously been publicly disclosed will be discussed;
- do not answer questions that do not relate to the original media request;
- do not speculate or exaggerate;
- do not be defensive or argumentative;
- be concise, defuse negatives, correct fallacies or inaccuracies;
- do not go off the record; and
- avoid saying “no comment”.

The designated individual should follow up, read the article, view and, if possible, record the TV segment, or listen to the radio report to ensure its accuracy. Copies of any such media coverage and the designated employees’ notes should be forwarded to the Disclosure Committee.

Reviewing Analyst Draft Reports and Models

DRI Healthcare will generally not review analysts’ draft research reports or models. However, in order to prevent dissemination of inaccurate information, DRI Healthcare may, as necessary, review a report or model for the purpose of pointing out errors in fact based on publicly disclosed information. With respect to an analyst’s estimates or projections, DRI Healthcare’s policy is not to comment on or question an analyst’s assumptions unless they are not realistic in view of previously disclosed historical information or other publicly available information. DRI Healthcare will not confirm, or attempt to influence, an analyst’s opinions or conclusions and will limit its comments on the analyst’s model and earnings estimates as described above. Under no circumstances should the designated Spokesperson comment on any forecasts, projections or other forward-looking information contained in a draft analyst’s report or model.

Distributing Analyst Reports

Analyst reports are proprietary products of the analyst’s firm. As a general rule, DRI Healthcare will not re-circulate any analyst reports. However, there may be instances where it is determined that providing analyst reports to third parties is prudent under the circumstances. In such cases, DRI Healthcare will not provide analyst reports through any means to persons outside of DRI Healthcare without the explicit written consent of the analyst. If DRI Healthcare provides an analyst report to a third party, with the explicit written consent of the analyst, then DRI Healthcare shall also provide a fair and balanced representative sample of multiple analyst reports to such third party, and shall refrain from including any commentary or endorsement of specific analyst reports to such third party. Any re-circulation of analyst reports shall be accompanied by an appropriate disclaimer, clarifying that DRI Healthcare has not reviewed or verified any of the information contained in such analyst reports, and the re-circulation of such reports shall not constitute an



endorsement of the content enclosed. DRI Healthcare will not post such reports on its website but may post a complete list, regardless of the recommendation, of all the investment firms and analysts who provide research coverage on DRI Healthcare. If provided, such list will not include links to the analysts' websites or publications.

Forward-looking Information

Should DRI Healthcare elect to disclose forward-looking information (“**FLI**”) in Disclosure Statements, the following guidelines will be observed:

1. The information, if deemed material, will be broadly disseminated via news release, in accordance with this Policy (i.e., at or before the time of disclosing the FLI).
2. The document or oral statement containing the FLI will contain the following cautionary language, proximate to the FLI:
 - (a) A statement identifying the FLI as “forward-looking information”;
 - (b) A statement that actual results may vary from the FLI and identifying material factors that could cause actual results to differ materially from the FLI; and
 - (c) A statement of the specific material factors or assumptions that were applied in making the FLI.
3. There must be a reasonable basis for the FLI.
4. The disclosure of FLI will be accompanied by a statement that disclaims DRI Healthcare’s intention or obligation to update or revise the FLI, whether as a result of new information, future events or otherwise, except as may be required by applicable securities laws, rules or policies. Notwithstanding this disclaimer, should subsequent events prove past statements about current trends to be materially off target, DRI Healthcare may choose to issue a news release explaining the reasons for the difference. In this case, DRI Healthcare will update its guidance on the anticipated impact on revenue and earnings (or other key metrics).
5. Where the FLI is about prospective financial performance, results of operations, financial position or cash flows, it must be accompanied by such additional cautionary language and comply with such other requirements as may be required by law.

When material Forward-Looking Information has been previously disclosed in written communications, including in any disclosure filed with securities regulators or posted on DRI Healthcare’s website, in addition to observing the general guidelines set out above, DRI Healthcare will include a discussion in its MD&A of events and circumstances that occurred during the MD&A period that are reasonably likely to cause actual results to differ materially from such previously disclosed material Forward-Looking Information, including a discussion of the expected differences. Should a determination be made to withdraw previously disclosed material Forward-Looking Information, the MD&A will include a discussion of the events and circumstances that led to the decision, including a discussion of the underlying assumptions that are no longer valid.

If DRI Healthcare provides forward-looking information about prospective financial performance, financial position or cash flows that is based on assumptions about future economic conditions and courses of action (whether such forward-looking information is presented in the format of a historical statement of financial position, statement of comprehensive income or statement of cash flows or not) (“**Financial FLI**”), then, in addition to observing the general guidelines set out above, DRI Healthcare will:

1. Obtain authorization from the Audit Committee of the Board of Trustees and the Audit Committee of the Board of Trustees will endeavour to ensure that there is a reasonable basis for drawing any conclusions or making any forecasts or projections set out in the forward-looking information.
2. only disclose Financial FLI that is limited to a period for which the information in the Financial FLI can be reasonably estimated and uses the same accounting policies the Trust expects to use to prepare its historical financial statements for the period covered by the Financial FLI;
3. state the date management approved the Financial FLI, if the document containing the Financial FLI is undated;
4. include disclosure that explains the purpose of the Financial FLI and cautions readers that the information may not be appropriate for other purposes; and
5. disclose in its MD&A material differences between actual results and previously released material Financial FLI for the period covered by the MD&A.

When Forward-Looking Information is disclosed through oral communications, including conference calls and speeches, the applicable Spokesperson will observe the general guidelines relating to FLI above, but may direct individuals to the Trust's publicly available documents for additional information about material factors or assumptions used in the preparation of the FLI and material risk factors and uncertainties that may cause actual results to differ from the FLI.

Disclosure Record

The Trust will maintain a six-year file containing all public information about the Trust, including continuous disclosure documents, news releases, analysts' reports and transcripts or recordings of conference calls.

Responsibility for Electronic Communications

This Policy also applies to electronic communications. Accordingly, individuals responsible for written and oral public disclosures shall also be responsible for electronic communications.

The Executive Chair and CEO of the Trust shall also be responsible for responses to electronic inquiries. Only public information or information which could otherwise be disclosed in accordance with this Policy shall be utilized in responding to electronic inquiries. In order to ensure that no material undisclosed information is inadvertently disclosed, employees are prohibited from participating in Internet chat rooms or newsgroup discussions on matters pertaining to DRI Healthcare's activities or its securities.

Website

The Executive Chair and CEO of the Trust are responsible for updating the investor relations section of DRI Healthcare's website and are responsible for monitoring all Trust information placed on the website to ensure that it is accurate, complete, up-to-date and in compliance with relevant securities laws.

The Disclosure Committee must approve all links from DRI Healthcare's website to a third-party website. Any such links will include a notice that advises the reader that they are leaving DRI Healthcare's website and that DRI Healthcare is not responsible for the contents of the other site.

Investor relations material shall be contained within a separate section of DRI Healthcare's website and shall include a notice that advises the reader that the information posted was accurate at the time of posting,



but may be superseded by subsequent disclosures. Any material changes in information must be updated immediately after such material changes are disclosed to the public. The minimum retention period on the website for financial statements and annual reports shall be two years and for supplementary information packages shall be one year.

Disclosure on DRI Healthcare's website alone does not constitute adequate disclosure of information that is considered material non-public information. Any disclosures of Material Information on DRI Healthcare's website will be preceded by the issuance of a news release.

Social Media

Only Spokespersons or other appropriate personnel as designated by the Disclosure Committee (each an "Authorized Social Media Spokesperson") are authorized to post, publish or distribute material about DRI Healthcare using authorized social media channels for purposes of DRI Healthcare's marketing, investor relations or other business purposes. Information relating to DRI Healthcare, including investor relations material, disclosed through social media should be viewed as an extension of DRI Healthcare's formal corporate disclosure record. Authorized Social Media Spokespersons must exercise care in ensuring that social media communications: (a) provide sufficient detail, and are presented in an appropriate manner, to ensure that social media users are able to understand the substance and significance of the information being discussed; are not overly promotional or exaggerated or otherwise inconsistent with information already disclosed by DRI Healthcare; are factual and balanced, giving unfavourable news equal prominence to favourable news; and (d) provide the same cautionary statements, safe harbour disclaimers and other required disclosure (e.g., regarding forward-looking information and non-IFRS financial measures) as are required to be included in related press releases, and if such complete disclosure is impractical for a particular social media platform (e.g., due to character limits), a link to the full disclosure should be included as a prominent part of the social media disclosure.

Communication and Enforcement

This Policy shall be available to all persons to which this Policy applies. This Policy extends to all trustees and certain executive officers and employees of DRI Healthcare, as determined by the CEO or the CFO from time-to-time, and any authorized spokespersons. New personnel will be provided with a copy of this Policy if the CEO or CCO deems it advisable due to the nature of the employees' role. This Policy shall be posted and maintained on DRI Healthcare's intranet.

Any employee who violates this Policy may face disciplinary action up to and including termination of employment without notice. The violation of this Policy may also violate certain securities laws. If it appears that an employee may have violated such securities laws, DRI Healthcare may refer the matter to the appropriate regulatory authorities, which could lead to penalties, including fines and/or imprisonment.

Date: July 1, 2025, amended on March 3, 2026

Appendix A

INFORMATION THAT MAY BE MATERIAL

The following are examples of the types of events or information that may be material. Most of these examples are taken from National Policy 51-201 – *Disclosure Standards*. This list is not exhaustive and is not a substitute for parties exercising their own judgement in making materiality determinations.

Changes in Corporate Structure

- changes in share ownership that may affect control of DRI Healthcare;
- major reorganizations, amalgamations, or mergers; or
- take-over bids, issuer bids, or insider bids.

Changes in Capital Structure

- the public or private sale of additional securities;
- planned repurchases or redemptions of securities;
- planned splits of units or offerings of warrants or rights to buy units;
- any share consolidation, share exchange, or stock dividend;
- changes in a company's distribution payments or policies, or the suspension or reinstatement of distributions;
- the possible initiation of a proxy fight; or
- material modifications to rights of security holders.

Changes in Financial Results

- a significant increase or decrease in near-term earnings prospects;
- unexpected changes in the financial results for any periods;
- shifts in financial circumstances, such as cash flow reductions, major asset write-offs or write-downs;
- changes in the value or composition of DRI Healthcare's assets; or
- any material change in DRI Healthcare's accounting policies.

Changes in Business and Operations

- any development that affects DRI Healthcare's royalties, the products underlying DRI Healthcare's royalties or markets;
- a significant change in investment plans or corporate objectives;
- disputes with major counterparties to contracts;
- significant new royalties;
- changes to the Board of Trustees or executive officers, including the departure of DRI Healthcare's CEO or CFO (or persons in equivalent positions);
- the commencement of, or developments in, material legal proceedings or regulatory matters;
- waivers of corporate ethics and conduct rules for officers, trustees, directors and other key personnel;



- any notice that reliance on a prior audit is no longer permissible; or
- de-listing of the Trust's securities or their movement from exchange to another.

Acquisitions and Dispositions

- significant acquisitions or dispositions of royalties, securities or other interests; or
- acquisitions of other companies, including a take-over bid for, or merger with, another company.

Changes in Credit Arrangements

- the borrowing or lending, or otherwise incurring, of a significant amount of indebtedness;
- any mortgaging or encumbering of DRI Healthcare's assets;
- defaults under debt obligations, agreements to restructure debt, or planned enforcement procedures by a bank or any other creditors;
- changes in rating agency decisions; or
- significant new credit arrangements or issuance of debt securities.